ORIC

7.3454.61%
RA

Richard A. Heyman

Founder, Independent Chairman & Member of Scientific Advisory Board

Dr. Richard A. Heyman, also known as Rich, Ph.D. is Member of Clinical & Scientific Advisory Board of Attovia Therapeutics, Inc. Dr. Heyman is Director of The Salk Institute For Biological STUDIES, San Diego, California. Dr. Heyman serves as Director at Pelage Pharmaceuticals, Inc from October 2025. He is Scientific & Clinical Advisor Member at CoRegen, Inc. He is Chairman of the Board at Alterome Therapeutics, Inc. Dr. Heyman was an Independent Chairman of the Board of Enliven Therapeutics, Inc. since 2023. Dr. Richard is Scientific Founders of Architect Therapeutics, Inc. He is Board Observer of Alterome Therapeutics, Inc. He served as Director & Scientific Advisor at Enliven Therapeutics, Inc. until 2023. He served as a member of Enliven's board of directors since the closing of the Merger on February 23, 2023 and was appointed in connection with the closing of the Merger. Prior to the Merger. Dr. Heyman served as a member of the board of directors of Former Enliven since March 2021. He served as an Independent Chairman of Board of Directors at RayzeBio, Inc. since December 2022 until February 26, 2024. Dr. Heyman is an accomplished biotechnology veteran with operational experience. Dr. Heyman has a track record of taking a patient-centric approach and helping biotechnology companies create value for all stakeholders. He serves as an Independent Director at BCTG Acquisition Corp since September 08, 2020. He serves as independent Chairman at Vividion Therapeutics, Inc. He served as Independent Chairman of the Board of Directors at PMV Pharmaceuticals, Inc. since June 2020 until June 04, 2026 and serves as its Member of Scientific Advisory Board. He is a Science Partner for Nextech Invest and a member of the board of directors of Curebound. He Co-Founded Metacrine, Inc. & served its Director since September 2014 until March 23, 2023 and had been its Independent Chairman since June 2015 until March 23, 2023. He served as Chairman of the Board of Directors at Amunix Pharmaceuticals, Inc. from 2019 to 2021. Dr. Heyman is Founder and serves as Independent Chairman of ORIC Pharmaceuticals Inc. since May 2018 and has been its Director since March 2015 and serves as its Member of Scientific Advisory Board. Dr. Heyman is a Venture Partner for Arch Ventures L.P. He focuses in Biotechnology and Pharmaceuticals. He is co-Founder of BCTG Acquisition Corp. Dr. Heyman also served as President and Chief Executive Officer of ORIC Pharmaceuticals, Inc. from November 2015 to May 2016 and its Acting President and Chief Executive Officer from November 2017 to May 2018. Dr. Heyman serves as Life Science Advisor at Ventana Capital Management, LLC. Dr. Heyman has experience in the biotechnology and pharmaceutical industries. He served as Interim Chief Executive Officer at ORIC Pharmaceuticals Inc. from October 2015 until August 10, 2016. From August 2013 to April 2015. Dr. Heyman served as the Chief Executive Officer and President at Seragon Pharmaceuticals Inc. from August 2013 to April 2015 a San Diego-based biotech company developing Selective Estrogen Receptor Degraders (SERDs) targeting estrogen dependent cancers. In August 2014, Genentech/Roche acquired Seragon. Which he co-founded in 2013 and sold to Genentech (Roche) in August 2014. He focused on the development of Selective Estrogen Receptor Degraders (SERDs) targeting estrogen dependent cancers. He co-founded Aragon Pharmaceuticals, Inc. in 2009 and served as its Chief Executive Officer since August 2010. He served as President and Head of Research and Development at Aragon Pharmaceuticals, Inc. He is a co-Founder of Syndax Pharmaceuticals, Inc. He served as Senior Vice President of Drug Discovery at Kalypsys, Inc. since September 2006 and served as its Chief Scientific Officer. He Co-founded X-Ceptor Therapeutics Inc. in 1999 and served as its Chief Scientific Officer and Senior Vice President of Research. Dr. Heyman serves on the board of directors of Architect Therapeutics LLC, a biotechnology company, since 2023. He served as Senior Vice President for metabolic diseases of Exelixis Inc. for which he led San Diego research site. Dr. Heyman served positions of increasing responsibility with Ligand Pharmaceuticals including Vice President of Nuclear Receptor Discovery, where he was responsible for multiple drug discovery programs, including the successful discovery and development of Panretin (alitretinoin) and Targretin (bexarotene), retinoids approved for the treatment of cancer. He served as Vice President of Research at Ligand Pharmaceuticals. Dr. Heyman established and managed numerous collaborations with pharmaceutical companies that resulted in clinical-stage compounds and worked closely with corporate Partners to move compounds from the bench into the clinic. He served as a Member of Scientific Advisory Board at Avidity Biosciences Inc. He serves on the Board of Directors for Ymanity Therapeutics. He has been a Director of Vividion Therapeutics, Inc. since September 7, 2017. He served as an Independent Director of Gritstone bio, Inc. (formerly known as Gritstone Oncology, Inc.) since November 2015 until August 2022. He had been a Member of Therapeutic Advisory Board at aTyr Pharma Inc. since March 1, 2011. Dr. Heyman He serves as Vice Chair of the Board of Trustees of The Salk, Institute for Biological Studies and Board of Directors of the UCSD Moores Cancer Center. He served as a Member of Scientific Advisory Board at Rgenix, Inc. since November 09, 2015 until April 12, 2017. He served as Lead Independent Director of Yumanity Therapeutics Inc and Director since December 22, 2020 until June 07, 2022. He served as a Member of the Board of Directors of Yumanity, Inc. since May 2016. He served as a Director of Seragon Pharmaceuticals Inc. He served as a Director of Receptos, Inc. from July 2014 to August 27, 2015. He served as a Director of Organovo Holdings, Inc. since August 21, 2013 until August 17, 2016. He served as a Member of the Board of Directors of Aragon Pharmaceuticals, Inc. He is on the Board of Visitors at the University of California at San Diego Moores Cancer Center. He is Vice Chair of the Board of Trustees at the Salk Institute. He serves on the Board Foundation for the American Association for Cancer Research. He was a NIH postdoctoral fellow at the Salk Institute. He has more than a dozen issued patents and co-authored over 100 scientific publications. He is the author or inventor on more than 120 publications and patents. He has won numerous awards, including Ernst and Young San Diego Regional Entrepreneur of the Year and the Endocrine Society Outstanding Innovation Award. He trained at the Salk Institute. Dr. Heyman holds Ph. D. in Pharmacology from University of Minnesota and B. S. in Chemistry from University of Connecticut.

Positions